Atlas Trials

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Clinical trial NCT03912818 · TERMINATED

Trial details

NCT number
NCT03912818
Sponsor
Stanford University
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder AdenocarcinomaBladder Mixed AdenocarcinomaBladder Squamous Cell CarcinomaBladder Urothelial CarcinomaInfiltrating Bladder Urothelial Carcinoma Sarcomatoid VariantInfiltrating Bladder Urothelial Carcinoma With Giant CellsInfiltrating Bladder Urothelial Carcinoma With Glandular DifferentiationInfiltrating Bladder Urothelial Carcinoma With Trophoblastic DifferentiationInfiltrating Bladder Urothelial Carcinoma, Clear Cell VariantInfiltrating Bladder Urothelial Carcinoma, Micropapillary VariantInfiltrating Bladder Urothelial Carcinoma, Nested VariantInfiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
Start date
2019-04-10
Primary completion
2022-08-11
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.